May 14, 2021 7:32 am EDT MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
May 13, 2021 7:30 am EDT MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
May 05, 2021 7:30 am EDT MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics